Debiopharm International Sa

This early-phase study tested a new drug called RP-6306 combined with the chemotherapy gemcitabine in 67 adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety, find the best dose, and see if the combination could sh…

This early-phase study tested an oral drug called Debio 0123 combined with the chemotherapy carboplatin in 76 adults with advanced solid tumors that had come back or worsened after prior platinum-based treatment. The main goals were to find the safest dose and check for side effe…

This early-phase study tested a new drug (Debio 0123) combined with standard chemotherapy in 34 adults whose small cell lung cancer returned after prior treatment. The main goals were to find a safe dose and check for side effects. The study was stopped early, so results are limi…

This early-stage study tested a new drug (RP-6306) combined with standard chemotherapy (FOLFIRI) in 38 adults with advanced solid tumors, including colorectal, GI, and esophageal cancers that had stopped responding to other treatments. The main goals were to check safety, find th…

This study tested a new antibiotic called afabicin for people with bone or joint infections caused by staph bacteria. It compared afabicin to standard antibiotics to see if it was safe and worked well. The study was stopped early, so results are limited.

This early-stage study tested a new formulation of octreotide (Debio 4126) that lasts 12 weeks, aiming to control hormone levels in people with acromegaly or certain neuroendocrine tumors. Only 19 participants were enrolled before the study was terminated. The goal was to measure…